Tumor Models



Cell line-derived xenograft (CDX) tumor models

1.280+ validated models covering full range of cancer types

2.77+ cell lines derived from PDX models

3.Available data of sensitivities to SOC (standard of care)

4.Imaging-based orthotopic/metastatic tumor models

5.Brain/bone metastatic models of lung/breast cancer cell lines


Patient-derived xenograft (PDX) tumor models

1.1380+ PDX models covering full range of cancer types

2.Fully-characterized models with genetic, molecular and pharmacological profiling

3.Drug-resistant PDX models available vitro screening and derivative PDXC/PDXO models

5.IO-PDX panel with hPBMC humanization


Syngeneic tumor models

1.70 Syngeneic models (mouse, rat, hamster)

2.Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)

3.Tumor-infiltrating leukocytes (TILs) map

4.WES, RNA-seq and scRNA-seq characterization


Genetically engineered models

1.48 engineered cell lines based on construct overexpression or gene knock-in

2.Pharmacologically validated in vitro and in vivo

3.Focusing at drug-resistant mutation introduction and IO-related checkpoint humanization

4.Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1, etc.


Human immune checkpoint gene KI mouse model

  1. KI (Knock-in) mice offer the possibility to study clinical grade targeting human immune-regulators in the context of a fully functional immune system

  2. Efficacy studies in different mouse strains with human targets KI in mice and cell lines

  3. Comprehensive flow cytometry to evaluate target expression and immune function


Immuno-avatar humanized models

  1. Mouse models harboring human tumor and human immune ceils

  2. Three different diagram of hPBMC humanization for mature T cell engraftment

  3. HSC (CD34+) avatar and next generation immune avatar for multiple-lineage engraftment (Myeloid, NK, DC etc.)

  4. IO-CDX and IO-PDX models with cancer targets and HLA information


Drug-resistant models

  1. Engineered cell line derived xenograft models

  2. Acquired drug-resistant CDX and PDX models

  3. Intrinsic drug-resistant PDX models


Rat models

1.20 human cell lines covering 11 cancer types (rat xenograft)

2.3 rat glioma syngeneic models

3.2 hamster syngeneic models

4.Available data of sensitivities to SOC (Standard of care)

5.Imaging-based orthotopic/metastatic models in development

6.Pharmacokinetic and pharmacodynamics studies